Boundless Bio公司宣布,其研发的BBI-940新药临床试验申请已正式获得监管机构批准。这一重要进展为公司在2026年上半年启动首个人体临床试验奠定了坚实基础,标志着该创新疗法向临床转化迈出关键一步。
Boundless Bio公司宣布,其研发的BBI-940新药临床试验申请已正式获得监管机构批准。这一重要进展为公司在2026年上半年启动首个人体临床试验奠定了坚实基础,标志着该创新疗法向临床转化迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.